Skip to Main Content

Talk about getting ahead of yourself.

Last June, Celator Pharmaceuticals proudly displayed a large poster touting its experimental Vyxeos medication as an effective salve for treating acute myeloid leukemia. The poster was, in fact, one of countless placards featured prominently on the exhibit floor at the American Society of Clinical Oncology meeting in Chicago, a sort of Woodstock for cancer doctors and eager investors.


Despite the numerous displays, however, the Celator poster managed to stick out.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.